Compare Novavax Inc (NVAX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Under Armour Inc Class A — how do they compare? Novavax Inc trades at $8.14 (market cap $1.31B), while Under Armour Inc Class A trades at $5.38 (market cap $2.23B). The key difference: Under Armour Inc Class A is the larger of the two by market cap. Which is the better fit depends on your goals.
| NVAX | UAA | |
|---|---|---|
Market Cap | $1.31B | $2.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $8.14 |
52-Week Low | $6.22 | $4.17 |
Enterprise Value | $890.95M | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.
The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.
Under Armour (UAA) trades at $5.35, up 0.26% today, amid a challenging fundamental backdrop. The stock shows a bearish technical trend with mixed sentiment, as recent earnings beat estimates but revenue declined. Key risks include weak North American demand and negative cash flow, while analysts maintain a cautious 'Hold' consensus with a $6.67 price target.
The outlook remains pressured by declining sales and profitability, though cost controls offer some stability. Investment opportunity hinges on a successful turnaround in key markets, but high execution risk and macroeconomic headwinds suggest limited near-term upside for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
